Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

Front-line consolidation with CAR-t therapy in newly diagnosed adult ph-negative b-acute lymphoblastic leukemia: Results from a prospective, phase 2 study

Runxia Gu, Shaowei Qiu, Wenbing Liu, Xiaoyuan Gong, Shuning Wei, Guangji Zhang, Benfa Gong, Qiuyun Fang, Shouyun Li, Kaiqi Liu, Dong Lin, Ying Wang, Chunlin Zhou, Chengcai Guo, Bingcheng LIU, Yingchang Mi, Hui Wei, Ying Wang, Jianxiang Wang

Blood (2025) 146 (Supplement 1): 1561.

https://doi.org/10.1182/blood-2025-1561

Published: 2025

Journal Articles

Treatment-free remission in patients with chronic myeloid leukemia following the second discontinuation of tyrosine kinase inhibitors

Yingling Zu, HUIFANG ZHAO, Yongping Song, Bingcheng LIU, Li Weiming, Qian Jiang, Yanli Zhang

Blood (2025) 146 (Supplement 1): 7302.

https://doi.org/10.1182/blood-2025-7302

Published: 2025

Journal Articles

Synergistic integration of CAR-T cell pharmacokinetics and NGS-MRD evolution enables precision risk stratification in relapsed/refractory B-cell acute lymphoblastic leukemia

Runxia Gu, Shuning Wei, Shaowei Qiu, Xiaoyuan Gong, Guangji Zhang, Benfa Gong, Qiuyun Fang, Shouyun Li, Kaiqi Liu, Dong Lin, Ying Wang, Chunlin Zhou, Bingcheng LIU, Yingchang Mi, Hui Wei, Jianxiang Wang, Ying Wang

Blood (2025) 146 (Supplement 1): 3366.

https://doi.org/10.1182/blood-2025-3366

Published: 2025

Journal Articles

This is a title in sentence case: Venetoclax-based regimens versus intensive chemotherapy in fit older adults with newly diagnosed acute myeloid leukemia (AML)：a multicenter, prospective, randomized phase II trial

Qiuyun Fang, Fei Li, Aijun Liao, Qingsong Yin, Lin Yang, Lianrong Xu, Junjie Ma, Junqing Xu, Hao Zhang, Jieyu Wang, Shaowei Qiu, Bingcheng LIU, Yingchang Mi, Jianxiang Wang, Hui Wei

Blood (2025) 146 (Supplement 1): 650.

https://doi.org/10.1182/blood-2025-650

Published: 2025

Journal Articles

Olverembatinib-mediated deep remission improves allogeneic stem cell transplantation outcome in patients with blast crisis chronic myeloid leukemia: First real-world practice report

Xiaoyu Zhang, Bingcheng LIU, Weihua Zhai, Qiaoling MA, Donglin Yang, Aiming Pang, Sizhou Feng, Mingzhe Han, Yi He, Hui Wei, Erlie Jiang

Blood (2025) 146 (Supplement 1): 1999.

https://doi.org/10.1182/blood-2025-1999

Published: 2025

Journal Articles

Olverembatinib (HQP1351) demonstrates efficacy vs. best available therapy (BAT) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant chronic-Phase chronic myeloid leukemia (CML-CP) in a registrational randomized Phase 2 trial: Up to 4-year follow-up including patients without T315I mutations

Blood (2025) 146 (Supplement 1): 3788.

https://doi.org/10.1182/blood-2025-3788

Published: 2025

Journal Articles

Treatment-free remission outcomes in pediatric chronic myeloid leukemia: Second-generation TKIs vs. Imatinib–a real-world multicenter study from China

HUIFANG ZHAO, Yu Zhu, Na Xu, QINGSHU ZENG, Shuxia Guo, Li xin Liang, Bingcheng LIU, Weiming Li, Qian Jiang, Yanli Zhang

Blood (2025) 146 (Supplement 1): 3786.

https://doi.org/10.1182/blood-2025-3786

Published: 2025

Journal Articles

Updated efficacy and safety of olverembatinib (HQP1351) as second-line therapy in patients (pts) with chronic Phase-chronic myeloid leukemia (CP-CML)

Li Weiming, Yanli Zhang, Huangling Zhu, Yunfan Yang, Na Xu, Bingcheng LIU, Fang Cheng, Zi Chen, Wei Chu, Yifan Zhai, Yu Hu

Blood (2025) 146 (Supplement 1): 3782.

https://doi.org/10.1182/blood-2025-3782

Published: 2025

Journal Articles

The efficacy and safety of switching to olverembatinib or continuing original TKI therapy in CML-CP patients treated with at least two prior TKIs: A prospective, multicenter, controll trial

Bingbing Wen, Junchong Peng, Bingcheng LIU, Jian Huang, Xin Du

Blood (2025) 146 (Supplement 1): 3779.

https://doi.org/10.1182/blood-2025-3779

Published: 2025

Journal Articles

Efficacy of tgrx-678, a potent BCR::ABL1 allosteric inhibitor, in CML-CP and CML-AP patients harboring T315I mutation: Results from a phase 1 study

Qian Jiang, Weiming Li, Yanli Zhang, Qiang WANG, Suning Chen, Bingcheng LIU, Jie Jin, Zhenfang Liu, Zhuogang Liu, Jianyu Weng, Xin Du, Xielan Zhao, Li Meng, Shujie Yan, xiaomeng Dong, Yihan Wang, Jingrong Cao

Blood (2025) 146 (Supplement 1): 902.

https://doi.org/10.1182/blood-2025-902

Published: 2025

Journal Articles

Single CAR-t infusion during front-line consolidation induces deep and sustained remission in newly diagnosed adult ph+b- ALL: A prospective phase 2 study

Runxia Gu, Shaowei Qiu, Xiaoyuan Gong, Shuning Wei, Guangji Zhang, Benfa Gong, Qiuyun Fang, Shouyun Li, Kaiqi Liu, Dong Lin, Ying Wang, Chunlin Zhou, Chengcai Guo, Bingcheng LIU, Yingchang Mi, Hui Wei, Ying Wang, Jianxiang Wang

Blood (2025) 146 (Supplement 1): 442.

https://doi.org/10.1182/blood-2025-442

Published: 2025

Journal Articles

Inotuzumab Ozogamicin Administration in First Remission Results in Profound and Safe Minimal Residual Disease Eradication in Adult Patients with Ph-Negative Acute Lymphoblastic Leukemia: Findings from a Phase 2, Single-Arm Trial

Blood (2024) 144 (Supplement 1): 4199.

https://doi.org/10.1182/blood-2024-200713

Published: 2024

Journal Articles

Similar Efficacy and Distinct Safety Profile of Nilotinib, Dasatinib and Flumatinib in Chronic Myeloid Leukemia Patients Resistant or Intolerant to 1 st Line Imatinib

Bingcheng Liu, Ying Wang, Kaiqi Liu, Yan Li, Qiuyun Fang, Yuntao Liu, Xiaoyuan Gong, Chunlin Zhou, Benfa Gong, Guangji Zhang, Shaowei Qiu, Hui Wei, Yingchang Mi, Jianxiang Wang

Blood (2024) 144 (Supplement 1): 4533.

https://doi.org/10.1182/blood-2024-204887

Published: 2024

Journal Articles

Ponatinib 2-Year Efficacy, Safety and Health-Related Quality of Life in Patients with Philadelphia Chromosome-Positive Leukemia: An Open-Label, Multicenter, Phase 2 Clinical Trial in China

Blood (2024) 144 (Supplement 1): 6602.

https://doi.org/10.1182/blood-2024-208258

Published: 2024

Journal Articles

Olverembatinib As Second-Line (2L) Therapy in Patients (pts) with Chronic Phase-Chronic Myeloid Leukemia (CP-CML)

Li Weiming, Yanli Zhang, Huanling Zhu, Yunfan Yang, Na Xu, Bingcheng Liu, Zi Chen, Wei Chu, Yifan Zhai, Yu Hu

Blood (2024) 144 (Supplement 1): 480.

https://doi.org/10.1182/blood-2024-204996

Published: 2024

Journal Articles

Safety and Efficacy of Tgrx-678, a Potent BCR::ABL1 allosteric Inhibitor, in Patients with Tyrosine Kinase Inhibitor Resistant and/or Intolerant Chronic Myeloid Leukemia: Updated Results of Phase 1 Study Tgrx-678 -1001

Qian Jiang, Li Weiming, Yanli Zhang, Qiang Wang, Suning Chen, Bingcheng Liu, Zhuogang Liu, Jie Jin, Zhenfang Liu, Jianyu Weng, Xin Du, Xielan Zhao, Li Meng, Lie Lin, Wanlin Ye, Shujie Yan, Yihan Wang, Jingrong Cao

Blood (2024) 144 (Supplement 1): 477.

https://doi.org/10.1182/blood-2024-205300

Published: 2024

Journal Articles

Improved MRD Clearance By Incorporating Venetoclax into Pediatric-Inspired Regimen in Newly Diagnosed Adolescent and Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Xiaoyuan Gong, Qiuyun Fang, Runxia Gu, Shaowei Qiu, Kaiqi Liu, Dong Lin, Chunlin Zhou, Shuning Wei, Guangji Zhang, Benfa Gong, Yuntao Liu, Yan Li, Shouyun Li, Bingcheng Liu, Wang Ying, Hui Wei, Yingchang Mi, Jianxiang Wang

Blood (2024) 144 (Supplement 1): 2812.

https://doi.org/10.1182/blood-2024-199109

Published: 2024

Journal Articles

Olverembatinib 30 Mg Versus 40 Mg Every Other Day (QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP): A Multi-Center Propensity Score-Matched Analysis

Blood (2024) 144 (Supplement 1): 4529.

https://doi.org/10.1182/blood-2024-203533

Published: 2024

Journal Articles

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Blood (2024) 144 (18): 1951–1961.

https://doi.org/10.1182/blood.2024024761

Published: 2024

Includes: Supplemental data

Journal Articles

Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 1797.

https://doi.org/10.1182/blood-2023-179073

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Front-line consolidation with CAR-t therapy in newly diagnosed adult ph-negative b-acute lymphoblastic leukemia: Results from a prospective, phase 2 study

Treatment-free remission in patients with chronic myeloid leukemia following the second discontinuation of tyrosine kinase inhibitors

Synergistic integration of CAR-T cell pharmacokinetics and NGS-MRD evolution enables precision risk stratification in relapsed/refractory B-cell acute lymphoblastic leukemia

This is a title in sentence case: Venetoclax-based regimens versus intensive chemotherapy in fit older adults with newly diagnosed acute myeloid leukemia (AML)：a multicenter, prospective, randomized phase II trial

Olverembatinib-mediated deep remission improves allogeneic stem cell transplantation outcome in patients with blast crisis chronic myeloid leukemia: First real-world practice report

Treatment-free remission outcomes in pediatric chronic myeloid leukemia: Second-generation TKIs vs. Imatinib–a real-world multicenter study from China

Updated efficacy and safety of olverembatinib (HQP1351) as second-line therapy in patients (pts) with chronic Phase-chronic myeloid leukemia (CP-CML)

The efficacy and safety of switching to olverembatinib or continuing original TKI therapy in CML-CP patients treated with at least two prior TKIs: A prospective, multicenter, controll trial

Efficacy of tgrx-678, a potent BCR::ABL1 allosteric inhibitor, in CML-CP and CML-AP patients harboring T315I mutation: Results from a phase 1 study

Single CAR-t infusion during front-line consolidation induces deep and sustained remission in newly diagnosed adult ph+b- ALL: A prospective phase 2 study

Inotuzumab Ozogamicin Administration in First Remission Results in Profound and Safe Minimal Residual Disease Eradication in Adult Patients with Ph-Negative Acute Lymphoblastic Leukemia: Findings from a Phase 2, Single-Arm Trial

Similar Efficacy and Distinct Safety Profile of Nilotinib, Dasatinib and Flumatinib in Chronic Myeloid Leukemia Patients Resistant or Intolerant to 1 st Line Imatinib

Ponatinib 2-Year Efficacy, Safety and Health-Related Quality of Life in Patients with Philadelphia Chromosome-Positive Leukemia: An Open-Label, Multicenter, Phase 2 Clinical Trial in China

Olverembatinib As Second-Line (2L) Therapy in Patients (pts) with Chronic Phase-Chronic Myeloid Leukemia (CP-CML)

Safety and Efficacy of Tgrx-678, a Potent BCR::ABL1 allosteric Inhibitor, in Patients with Tyrosine Kinase Inhibitor Resistant and/or Intolerant Chronic Myeloid Leukemia: Updated Results of Phase 1 Study Tgrx-678 -1001

Improved MRD Clearance By Incorporating Venetoclax into Pediatric-Inspired Regimen in Newly Diagnosed Adolescent and Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Olverembatinib 30 Mg Versus 40 Mg Every Other Day (QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP): A Multi-Center Propensity Score-Matched Analysis

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only